Post-IPO stock offer preps Supernus for launch of epilepsy drugs
This article was originally published in Scrip
Supernus Pharmaceuticals has priced an underwritten public offering of six million shares of common stock at $8 per share for net proceeds of $44.7 million for the commercial launch of the newly public company's epilepsy drugs Oxtellar XR and Trokendi XR, clinical development of Phase II attention-deficit hyperactivity disorder (ADHD) drug candidates SPN-810 and SPN-812, and repayment of debt and other expenses.
You may also be interested in...
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.